

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis and Antiretroviral Evaluation of Various 5-Alkyl-6-AZA-5,6-Dihydrouridine

Jean Depelley^a; Robert Granet^a; Pierre Krausz^a; Salomon Piekarski^a; Claudine Bosgiraud^b; Sylvie Beaussoleil^b

^a Faculté des Sciences, Laboratoire de Chimie des Substances Naturelles, Limoges, cedex, (France) ^b U.F.R. de Pharmacie, Limoges, cedex, (France)

To cite this Article Depelley, Jean , Granet, Robert , Krausz, Pierre , Piekarski, Salomon , Bosgiraud, Claudine and Beaussoleil, Sylvie(1994) 'Synthesis and Antiretroviral Evaluation of Various 5-Alkyl-6-AZA-5,6-Dihydrouridine', *Nucleosides, Nucleotides and Nucleic Acids*, 13: 4, 1007 — 1010

To link to this Article: DOI: 10.1080/15257779408011873

URL: <http://dx.doi.org/10.1080/15257779408011873>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NOTE

SYNTHESIS AND ANTIRETROVIRAL EVALUATION OF VARIOUS 5-ALKYL-6-AZA-5,6-DIHYDROURIDINE

Jean Depelley, Robert Granet, Pierre Krausz* and Salomon Piekarski.


Laboratoire de Chimie des Substances Naturelles, Faculté des Sciences, 123 Av. Albert Thomas, 87060 Limoges cedex (France).

Claudine Bosgiraud and Sylvie Beaussolleil.

U.F.R. de Pharmacie, 2 rue du Docteur Marcland, 87025 Limoges cedex (France).


ABSTRACT : Various 5-alkyl-6-aza-5,6-dihydrouridine were synthesized from the corresponding triazinic heterocycles and acetylated ribose. These nucleosides were tested for inhibitory activity on lentivirus Visna-Maedi.

Although the chemistry and pharmacology of nucleosides have been widely and thoroughly studied, little has been undertaken in the case of dihydroazauracil derivatives despite promising biological activities.¹ As a part of our continuing effort to acquire new antiviral agents,² we report here the synthesis and preliminary antiretroviral activity of the modified nucleosides **1a,b,c**.



1a : R₁ = -H ; R₂ = -CH₃
1b : R₁ = -H ; R₂ = -(CH₂)₂CH₃
1c : R₁ = R₂ = -CH₃

The bases **2a,b,c** have been prepared according to a method developed previously in our laboratory.³



a : R₁ = -H, R₂ = -CH₃ ; **b** : R₁ = -H, R₂ = -(CH₂)₂CH₃ ; **c** : R₁ = R₂ = -CH₃.

i : 1,2,3,5-tetra-O-acetyl-ribofuranose (1 eq), TMSCl (0.8 eq), HMDS (0.8 eq), TMSTf (2.2 eq); **ii** : NH₃ in MeOH.

FIGURE 1

Among the different methods of coupling, the modified Vorbrüggen procedure^{4,5,6} was found to be the most effective. Thus, condensation of 2a,b,c with 1,2,3,5-tetra-O-acetyl-ribofuranose in 1,2-dichloroethane at 60°C during 15 mn led to protected dihydroazauracil nucleosides 3a,b,c and 4a,b,c⁷ (for experimental conditions see Fig. 1). The most efficient quantity of Lewis acid was found to be 2.2 eq of TMSTf.

The difficult separation of the acetylated N₁-nucleosides 3a,b,c and N₆-nucleosides 4a,b,c was achieved by silica gel column chromatography using as eluants AcOEt/pet.ether for compounds **a** and **c** and CHCl₃/EtOH for compounds **b**.

The N-linkage between the peracetylated ribose and bases reported here was assigned using ¹H nmr by observation of the anomeric proton of the ribose moiety and the H-1, H-3 and H-6 protons of the coupled dihydroazauracil (Table 1).

The shift of the anomeric proton of the N₁-nucleosides 3a,b,c was assigned at 6 ppm as with acetylated dihydrouridine.⁸ In the case of the N₆-nucleosides 4a,b,c, it appeared at 4.8 ppm as with ribofuranosylamines.⁹

These assignments were supported by irradiation of the H-2' proton leading to the decoupling of H-1' (and H-3' at 5.2 ppm).

Moreover, the observation of the protected N₆-nucleosides 4a,b,c showed the NH protons H-1 and H-3 while H-6 was not present. In the peracetylated N₁-nucleosides 3a,b,c, H-3 and H-6 were observed while H-1 was absent.

Compounds 3 and 4 were obtained from bases 2a,b,c with 15 %, 6 %, and 40 % overall yields respectively (with 3/4a = 2.75, 3/4b = 1, and 3/4c = 0.7).

We obtained chromatographically purified mixtures of diastereoisomers for compounds

TABLE 1 . Selected values of ^1H nmr data (200 MHz in CDCl_3).

Compounds	H-1' (ppm)	H-1 (ppm)	H-3 (ppm)	H-6 (ppm)
3a	6.0 $d(\text{J1}',2') = 5.9 \text{ Hz}$	-	7.55	4.4 m
3b	6.1 $d(\text{J1}',2') = 6.8 \text{ Hz}$	-	7.65	4.5 m
3c	6.0 $d(\text{J1}',2') = 5.8 \text{ Hz}$	-	7.4	4.45 s
4a	4.7 $d(\text{J1}',2') = 7.5 \text{ Hz}$	7.1	7.6	-
4b	4.8 $d(\text{J1}',2') = 6.9 \text{ Hz}$	7.1	7.65	-
4c	4.9 $d(\text{J1}',2') = 7.1 \text{ Hz}$	7.1	7.4	-

TABLE 2 : Cytotoxicity and EC50 of **1a,b,c**, AZT, ddC and ddU.

Compounds	EC50 (μM)		MCC (μM)	S I	
	Visna	Maedi		Visna	Maedi
1a	109.2	89.9	500	4.6	5.6
1b	/	/	400	/	/
1c	/	/	200	/	/
AZT	0.37	0.26	100	270	385
ddC	0.3	0.28	250	833	893
ddU	126.6	133.8	500	3.95	3.7

3a,b and **4a,b** due to their asymmetric carbon C-5. We were unsuccessful in the separation of the individual diastereoisomers.

The protecting groups of **3a,b,c** were removed by treatment with a saturated solution of ammonia in dry methanol (at 0°C) to give the desired nucleosides **1a,b,c** in nearly quantitative yields.¹⁰

The antiretroviral activities of **1a**, **1b**, and **1c** were compared to those of known nucleosides AZT, ddC and an inactive parent molecule of **1a,b,c** : ddU, for *in vitro* replication of the Visna-Maedi lentivirus (Visna virus : strain K796 and Maedi virus : strain WLC1) in Sheep Choroid Cells (SCP) (Table 2).

The minimal cytotoxic concentration (MCC) of both **1a** and ddU for actively dividing SCP cells was determined to be $500 \mu\text{M}$; **1c** was the most cytotoxic with a MCC of $200 \mu\text{M}$.

50 % effective concentration values (EC50) were determined by cytopathic effect inhibition assays (CPE).¹¹ EC50 values of **1b** and **1c** could not be determined because these compounds were not effective below their MCC.

A comparable inhibition to that of AZT and ddC, which are recognized to be the most active agents against Visna-Maedi virus, was not obtained for compounds **1a,b,c**. Modifications of the carbohydrate moiety of these dihydroazauracil nucleosides¹² are under investigation.

ACKNOWLEDGMENTS: This research was supported by A.N.V.A.R. (Association Nationale de Valorisation et d'Aide à la Recherche). We gratefully thank Drs J.P. Célerié and A. Fleurant for the recording of ¹H nmr spectra, Dr Mauratille for mass spectra and J.M. Davis for her helpful comments on the English manuscript.

REFERENCES.

- 1 . Skulnick, H. *J. Org. Chem.*, **1978**, *43*, 3188.
- 2 . Czernecki, S.; Ezzitouni, A.; Krausz, P. *Synthesis*, **1990**, *8*, 651.
- 3 . Granet, R.; Piekarski, S. *C. R. Acad. Sci., Paris*, **1975**, *280*, 585.
- 4 . Vorbrüggen, H.; Bennua, B. *Chem. Ber.*, **1981**, *114*, 1256.
- 5 . Vorbrüggen, H.; Bennua, B. *Chem. Ber.*, **1981**, *114*, 1279.
- 6 . Vorbrüggen, H.; Bennua, B. *Chem. Ber.*, **1981**, *114*, 1234.
- 7 . Selected values of **3a,b,c** and **4a,b,c**.
For selected ¹H nmr data, see TABLE 1
3a : Rf 0.60 (AcOEt/pet. ether 4:1); MS *m/z* (EI) : 314 (M⁺ - AcOCH₂).
3b : Rf 0.20 (HCCl₃/EtOH 95:5); MS *m/z* (EI) : 417 (M + 2H)⁺.
3c : Rf 0.63 (AcOEt/pet. ether 4:1); MS *m/z* (EI) : 402 (M + H)⁺; [α]_D -8.4° (c 0.4, HCCl₃).
4a : Rf 0.42 (AcOEt/pet. ether 4:1); MS *m/z* (EI) : 389 (M + 2H)⁺.
4b : Rf 0.17 (HCCl₃/EtOH 95:5); MS *m/z* (EI) : 417 (M + 2H)⁺.
4c : Rf 0.46 (AcOEt/pet. ether 4:1); MS *m/z* (EI) : 403 (M + 2H)⁺; [α]_D -80.4° (c 0.3, HCCl₃).
- 8 . Skaric, V.; Gaspert, B.; Hohnjec, M.; Lacan, G. *J.C.S. Perkin 1*, **1974**, 267.
- 9 . Chavis, C.; de Gourcy, C.; Imbach, J.L. *Carbohydr. Res.*, **1984**, *135*, 13.
- 10 . Selected data for **1a,b,c**.
1a : Rf 0.45 (HCCl₃/EtOH 7:3); MS *m/z* (FAB) : 262 [(M + H)⁺].
1b : Rf 0.55 (HCCl₃/EtOH 7:3); MS *m/z* (FAB) : 290 [(M + H)⁺].
1c : Rf 0.63 (HCCl₃/EtOH 7:3); MS *m/z* (FAB) : 276 [(M + H)⁺].
- 11 . Beaussoleil, S.; Bosgiraud, C.; Nicolas, J.A. *Rev. Med. Vet.*, **1991**, *142* (7), 557.
- 12 . Beaussoleil, S.; Bosgiraud, C.; Depelley, J.; Granet, R.; Krausz, P.; Nicolas, J.A.; Piekarski, S. Brevet Français N° 9202401 (28/2/92).

Received 2/23/93

Accepted 10/18/93